Evaluation of an online tool providing management guidance for adverse events associated with immune checkpoint inhibitors.

Abstract

e18131 Background: Immune checkpoint inhibitors (ICIs) are altering the treatment paradigm in oncology; but many healthcare providers (HCPs) are still unfamiliar with ICIs and the unique associated immune-related adverse events (irAEs). An online tool was developed to give HCPs easy access to fair-balanced guidance and algorithms that extend beyond standard recommendations found in the respective product inserts. Methods: Tool users input patient symptoms, organ system affected, and the grade of the event along with their planned management strategy; they were then provided an expert recommendation to guide management of that specific irAE. Recommendations in the tool comprised algorithms developed from peer-reviewed studies and personal clinical experience of several experienced physicians. Case entries (collected from 11/9/16 through 1/17/17), variation of intended management with recommended management, and impact on practice were analyzed. Results: To date, 918 unique tool queries have been entered by HCPs. Cases of GI symptoms were most frequently (29% of all cases) entered into the tool (Table). The planned management of pulmonary- and endrocrine-related AEs differed from expert recommendations for the highest percentage of cases (53% and 65%, respectively). Overall, the intended management plans differed from expert recommendations in 49% of HCP tool queries. Most (93%) HCPs indicated that this online tool either changed their management plan or that their planned strategy was reinforced by using this tool. Conclusions: These data suggest that many HCPs are challenged to manage irAEs associated with ICIs and that an online tool can provide a resource to improve patient care and safety. A detailed analysis of the tool, including case entries and planned management vs expert recommendation for each irAE and grade will be presented. [Table: see text]